Allen Hunt
Overview
Explore the profile of Allen Hunt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Chen W, He X, He A, Zhao L, Xie T, et al.
Diabetes Obes Metab
. 2025 Mar;
PMID: 40028667
Aims: GZR18, a novel long-acting GLP-1 receptor agonist, has demonstrated substantial metabolic improvements in diabetic and obese animal models. The present studies aimed to evaluate the safety, tolerability, pharmacokinetics (PK)...
2.
Xu G, Paglialunga S, Qian X, Ding R, Webster K, van Haarst A, et al.
Front Immunol
. 2024 Dec;
15():1495540.
PMID: 39717777
Background: Alarmins mediate type 2 T helper cell (Th2) inflammation and serve as upstream signaling elements in allergic inflammation and autoimmune responses. The alarmin interleukin (IL)-25 binds to a multi-domain...
3.
Dworaczyk D, Hunt A, Di Spirito M, Lor M, Rance K, van Haarst A
Ann Allergy Asthma Immunol
. 2024 May;
133(2):186-193.e2.
PMID: 38719149
Background: Nasal congestion could affect the absorption of an epinephrine nasal spray (ENS). Objective: To compare the pharmacokinetics of 13.2 mg ENS with nasal congestion vs without congestion and vs...
4.
Yin W, Ballard T, Zhu S, Hsiao S, Chen H, Li Y, et al.
Br J Clin Pharmacol
. 2023 Sep;
90(2):516-527.
PMID: 37771051
Aims: Our aim was to determine the absolute bioavailability, mass balance, metabolism and excretion of soticlestat (TAK-935). Methods: An open-label, two-period, single-site, phase 1 study was conducted in six healthy...
5.
Yamamiya I, Hunt A, Yamashita F, Sonnichsen D, Muto T, He Y, et al.
Clin Pharmacol Drug Dev
. 2023 Jun;
12(9):927-939.
PMID: 37300358
Futibatinib, a selective, irreversible fibroblast growth factor receptor 1-4 inhibitor, was recently approved for FGFR2 rearrangement-positive cholangiocarcinoma. This Phase I study evaluated the mass balance and metabolic profile of C-futibatinib...
6.
Yamamiya I, Hunt A, Takenaka T, Sonnichsen D, Mina M, He Y, et al.
Clin Pharmacol Drug Dev
. 2023 May;
12(10):966-978.
PMID: 37132707
Futibatinib, a selective, irreversible fibroblast growth factor receptor 1-4 inhibitor, is being investigated for tumors harboring FGFR aberrations and was recently approved for the treatment of FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma....
7.
Yamamiya I, Hunt A, Yamashita F, Sonnichsen D, He Y, Benhadji K
Clin Pharmacol Drug Dev
. 2022 Nov;
12(3):294-303.
PMID: 36382853
Futibatinib, an oral, irreversible fibroblast growth factor receptor (FGFR) 1-4 inhibitor, is being evaluated for FGFR-aberrant tumors. Two open-label phase 1 studies evaluated the effects of high-fat, high-calorie food and...
8.
Aliprantis A, Wolford D, Caro L, Maas B, Ma H, Montgomery D, et al.
Clin Pharmacol Drug Dev
. 2020 Oct;
10(5):556-566.
PMID: 33125189
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infection and related morbidity and mortality in infants. Passive immunization with an RSV-neutralizing antibody can provide rapid...
9.
Hunt A, Faybishenko B, Ghanbarian B, Egli M, Yu F
Int J Environ Res Public Health
. 2020 Jan;
17(3).
PMID: 31979264
The fate of water and water-soluble toxic wastes in the subsurface is of high importance for many scientific and practical applications. Although solute transport is proportional to water flow rates,...